多发性硬化(MS)的复发缓解型(RRMS)患者中约50%在10年内转变成继发进展型(SPMS)，中医认为MS湿热证患者常反复发作、迁延不愈，具有湿性重浊粘滞的特征。而中药在MS防复发中作用明显，但核心证候研究不足、缺乏客观指标，无法突显中医优势。血清生物标记物是西医辅助诊断MS、预测疾病进展的客观指标，若能从血清生物标记物层面揭示MS湿热证患者的生物学基础，亦可阐明MS湿热证候特征及“病证”演变趋势，为中医在治疗、防复发等方面提供佐证。重组cDNA表达克隆血清学鉴定技术(SEREX)是筛选MS特异性生物标记物的有效方法，因此本研究采集RRMS和SPMS的湿热证、非湿热证患者四诊信息和血清样本，应用SEREX技术筛选RRMS和SPMS的湿热证、非湿热证相关靶抗原，更有助于获得MS证候相关客观指标。本项目为研究MS核心证候提供新的思路和方法，为中医精准治疗、探索并寻找中药新靶点等方面提供依据。

In multiple sclerosis, about 50% of recurrent-remission (RRMS) patients are converted to secondary-progressive (SPMS) within 10 years. Traditional Chinese medicine (TCM) considered that damp-heat characterized by turbidity heavy and viscosity is an important factor in MS recurrent. However, the objective basis or mechanisms for evolution of traditional Chinese medicine (TCM) syndromes was insufficient. Serum biomarkers are objective indicators of modern medicine assisted diagnosis and prediction of disease progression in MS. Accordingly, if the objective biological basis of MS damp-heat syndrome could be revealed from the level of serum biomarkers, the objectification for TCM treatment will be remarkably promoted. It is noteworthy that recombinant cDNA expression clone serology identification technology (SEREX) technology has been shown to be an effective method for screening new serum heterosexual biomarkers in MS. Therefore, SEREX technology was employed to screen damp-heat syndrome and Non- damp-heat syndrome related serum biomarkers in RRMS and SPMS, which will be more helpful to obtain related serum biomarkers and provide objective indicators for MS damp-heat syndrome and syndromes evolution. This project will provide a new perspective and method for the study of MS damp-heat syndrome theory, and lay favorable foundation for the precise treatment and exploration of new targets of TCM for patients with MS damp-heat syndrome.